Susquehanna International Group’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-47,400
| Closed | -$141K | – | 10578 |
|
|
2016
Q3 | $141K | Sell |
47,400
-9,100
| -16% | -$15.8K | ﹤0.01% | 7806 |
|
|
2016
Q2 | $84K | Sell |
56,500
-4,400
| -7% | -$10.1K | ﹤0.01% | 8101 |
|
|
2016
Q1 | $225K | Sell |
60,900
-242,000
| -80% | -$1.5M | ﹤0.01% | 7784 |
|
|
2015
Q4 | $3.06M | Buy |
302,900
+209,800
| +225% | +$2.53M | ﹤0.01% | 3241 |
|
|
2015
Q3 | $1.27M | Sell |
93,100
-2,800
| -3% | -$49.9K | ﹤0.01% | 5199 |
|
|
2015
Q2 | $1.82M | Sell |
95,900
-320,100
| -77% | -$6.93M | ﹤0.01% | 4935 |
|
|
2015
Q1 | $10.9M | Sell |
416,000
-281,700
| -40% | -$7.17M | ﹤0.01% | 1795 |
|
|
2014
Q4 | $14.6M | Buy |
697,700
+313,800
| +82% | +$7.91M | 0.01% | 1617 |
|
|
2014
Q3 | $12.8M | Buy |
383,900
+222,300
| +138% | +$6.9M | ﹤0.01% | 1844 |
|
|
2014
Q2 | $5.19M | Sell |
161,600
-937,600
| -85% | -$34.9M | ﹤0.01% | 3016 |
|
|
2014
Q1 | $50.7M | Buy |
1,099,200
+823,200
| +298% | +$48.3M | 0.02% | 626 |
|
|
2013
Q4 | $19.6M | Sell |
276,000
-396,700
| -59% | -$30.3M | 0.01% | 1369 |
|
|
2013
Q3 | $57.7M | Sell |
672,700
-44,300
| -6% | -$3.75M | 0.03% | 538 |
|
|
2013
Q2 | $45.4M | Buy |
+717,000
| New | +$38.1M | 0.03% | 613 |
|
Susquehanna International Group's AEGR Position: Q4 2016 in Review
Susquehanna International Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 76,709 shares — an estimated $228K sold.
Susquehanna International Group first reported a position in AEGR in Q2 2013 and held it in 13 quarters. The position peaked at $19.3M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Susquehanna International Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Susquehanna International Group sold 76,709 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $228K.
- Susquehanna International Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
- Susquehanna International Group's Aegerion Pharmaceuticals position peaked at $19.3M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Susquehanna International Group's 13F filing for Q4 2016, filed 14 Feb 2017.